Please login to the form below

Not currently logged in
Email:
Password:

GSK’s COPD drug Anoro under review in US

FDA accepts new drug application for the LAMA/LABA combination

GSK COPD Anoro FDA

GlaxoSmithKline's (GSK) investigational respiratory treatment Anoro is under review by the FDA after the US regulator accepted its new drug application.

GSK and its development partner Theravance submitted the medicine for approval to treat patients with chronic obstructive pulmonary disease (COPD), and the FDA is expected to make a decision by December 18, 2013.

Anoro is one of several COPD products in development that combine a long-acting muscarinic antagonist (LAMA) with a long-acting beta agonist (LABA), both of which are already used separately to treat respiratory conditions.

In the case of Anoro, the two molecules combined are the LAMA umeclidinium bromide (UMEC), also known as GSK573719, and the LABA vilanterol (VI), with the medicine intended to be administered using GSK's Ellipta inhaler.

The US submission follows Anoro's filing with the European Medicines Agency (EMA) in January 2013, and gives GSK a march over its rivals.

Boehringer's LAMA/LABA combination olodaterol/tiotropium has yet to be submitted for approval in either region, while Novartis' QVA149 (glycopyrronium bromide and indacaterol maleate) was filed for approval in Europe and Japan in October, but is not expected to be submited for FDA approval until 2014.

FDA priority review for ViiV Healthcare's HIV drug
GSK received separate good news in the past week when the FDA granted a priority review to the investigational HIV treatment dolutegravir.

The drug is being developed by ViiV Healthcare – a joint venture between GSK and Pfizer – and will now received an accelerated approval process, with the FDA expected to make a decision on dolutegravir's approval by August 17, 2013.

The FDA will review data from a phase III programme that demonstrated the integrase inhibitor was more effective than Gilead Sciences/Bristol-Myers Squibb's big-selling Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate), a fixed-dose triple therapy for HIV.

20th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

If you needed an organ transplant, would you have one?
Lauren Packer discusses the worsening problem in the UK with an imbalance between the number of organs needed, and the number of those being donated....
Why tugging at our heartstrings is no longer enough to make us open our purses
Charlotte Shyllon (Director and Partner) and Maren Thurow (Senior Account Executive), discuss the highly emotive Make a Child Cry campaign video from Doctors of the World (Médecins du Monde)....
quantify_messages.png
Exploring full potential of e-detailing data
Today’s high quality e-detailing data can create better quality conversations with healthcare professionals and result in improved access and relationships....

Infographics